Alkermes Announces Notice of Allowance of U.S. Patent for a Novel Fumarate Prodrug for Multiple Sclerosis

07-01-2014 Business Wire HealthComments (0)

AlkermesPharmaceutical

Alkermes plc (NASDAQ:ALKS) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 14/032,736, entitled “Prodrugs of fumarates and their use in treating various diseases.” The allowed composition of matter claims will cover Alkermes’ MMF prodrug, ALKS 8700, a proprietary, small-molecule prodrug of monomethyl fumarate (MMF) for the treatment of multiple sclerosis. The Notice of Allowance resu

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top